Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Glaxo Wellcome Changes Its Name to Glaxo SmithKline, Relocates Head Office
January 15, 2001
- Arimidex Approved as 1st Drug Based on Bridging Studies in Japan
January 15, 2001
- Dainippon Starts Full Operation of New PMS Information System
January 15, 2001
- BUSINESS NEWS IN BRIEF -1-
January 15, 2001
- Use of Overseas Data Recommended to Develop Pediatric Drugs
January 15, 2001
- Use New Technology to Meet Existing Needs in Healthcare: Mr Tanimura
January 15, 2001
- BUSINESS NEWS IN BRIEF -2-
January 15, 2001
- CPAC to Become Pharmaceutical Affairs and Food Sanitation Council
January 15, 2001
- Banyu Confirms Efficacy, Safety of Simvastatin in Clinical Trail
January 15, 2001
- CAPC's Executive Committee Recommends Approval of 16 Active Ingredients
January 15, 2001
- medical facilities & nursing care news on brief
January 15, 2001
- REGULATORY NEWS IN BRIEF -2-
January 15, 2001
- Cooperation with Companies Is Essential: RIKEN Researcher
January 15, 2001
- Sales of Takeda's Blopress Skyrocket: Top 100 Products Ranking
January 15, 2001
- Tissue Engineering Chair Donated by BCS at Tokai Univ.
January 15, 2001
- NHI Price System Reform Shelved in Japan: US ITC Report
January 15, 2001
- abbreviation
January 15, 2001
- Growth of Morphine Consumption Slows Down
January 15, 2001
- Welfide: Business Forecasts Affected by Transfer of Business, Shares
January 15, 2001
- REGULATORY NEWS IN BRIEF -1-
January 15, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…